Platform Deals Are Commanding Premiums — But Only for the Right Modalities

The Platform Premium Is Real, But Uneven

There's a widening gap in how pharma pays for platform companies versus single-asset biotechs — and the difference isn't just about upfront size. It shows up in milestone structures, option architectures, and how much of total deal value is actually achievable.

This isn't new in principle. Acquirers have always paid more for engines that can generate multiple programs. What has changed is the specificity of the premium. Not every platform gets rewarded equally. Across the deals we track, the modalities that command genuine platform premiums have narrowed to a handful: antibody-drug conjugates, targeted protein degradation, cell therapy manufacturing platforms, and certain flavors of RNA-based delivery. Meanwhile, companies positioning themselves as "AI-enabled discovery platforms" have seen the premium compress substantially from its 2021–2022 peak.

The practical question for any biotech founder going to market is no longer "do I have a platform?" It's "does my platform fit the categories where buyers are still paying platform economics?"

What Counts as a Platform Deal in 2026

Definitions matter here, because the word "platform" has been so thoroughly diluted that it barely means anything in pitch decks anymore. For the purposes of our analysis, we define platform transactions as deals where the acquirer or licensee explicitly gains rights to a technology engine, a library of compounds, or a manufacturing capability — not just a single lead program and its follow-on indications.

By that definition, the deal structures look fundamentally different. Platform transactions tend to carry higher upfronts as a percentage of total deal value, reflecting the buyer's willingness to pay for optionality they can exploit across their own pipeline. They also tend to include technology access fees or option-based structures that let the buyer nominate additional targets over time — a structure you almost never see in single-asset licensing deals.

The AbbVie/Cerebras Therapeutics deal in early 2026 is a useful public reference point. AbbVie paid a substantial upfront for access to Cerebras's radiopharmaceutical conjugate platform, with the right to nominate multiple targets over a defined period. Compare that to a more typical single-indication license, where the upfront is lower and the milestone stack is heavier on late-stage clinical and commercial triggers. The economics are structurally different animals.

Bristol Myers Squibb's approach to protein degradation — building relationships with multiple platform holders including recent extensions of existing collaborations — shows another pattern. Rather than acquiring platforms outright, some buyers are stacking option-based partnerships, effectively renting platform access while retaining the ability to walk away from underperforming targets. That structure protects the buyer but compresses economics for the platform holder unless the initial option payments are large enough to matter.

Modality Determines the Multiple

The most important variable in platform deal economics right now isn't stage, therapeutic area, or geography. It's modality.

ADC platforms are commanding the strongest premiums, and it's not close. The Pfizer/Seagen acquisition in 2023 set the anchor, and every subsequent ADC platform transaction has been priced against it. Buyers understand that ADC technology — linker-payload chemistry, conjugation methods, bystander-effect engineering — transfers across targets in a way that justifies genuine platform economics. The pipeline optionality is concrete and demonstrable.

Targeted protein degradation sits in a similar position, though the deal structures skew more toward multi-target collaborations than outright acquisitions. Novartis, Roche, and several mid-cap pharma companies have built networks of degrader platform partnerships, and the option payments in these deals have trended upward as the first wave of clinical data has started to validate the approach.

Cell therapy manufacturing platforms occupy an interesting middle ground. The platform premium here isn't about target diversity — it's about cost of goods and scalability. Companies that have solved autologous-to-allogeneic conversion, or that have developed differentiated in vivo approaches, are being valued as manufacturing infrastructure as much as therapeutic pipelines. The Johnson & Johnson/Legend Biotech relationship, while not new, continues to anchor how buyers think about the manufacturing platform premium.

Where the premium has faded most visibly is in computational and AI-driven discovery. In 2021 and 2022, deals like the Sanofi/Exscientia and Recursion/Roche collaborations carried substantial headline values. In our dataset, the more recent computational platform deals show lower upfronts as a share of total consideration, longer milestone ladders, and more buyer-favorable termination provisions. Buyers have gotten skeptical that AI-discovered molecules are fundamentally different from traditionally discovered ones by the time they reach IND. The platform story is harder to sustain when the output is a conventional small molecule.

Structure Tells the Real Story

Beyond headline numbers, the structural differences between platform and single-asset deals reveal where buyers see genuine value.

In platform deals, we see a higher frequency of option-exercise structures — where the buyer pays an initial access fee, then pays additional fees to nominate specific targets or programs. These option payments function like a rolling series of mini-upfronts, and for the seller, they create recurring revenue that can fund internal pipeline work. The best-structured platform deals generate enough option income to be financially self-sustaining for the biotech, which fundamentally changes the power dynamic in subsequent negotiations.

Single-asset deals, by contrast, continue to follow the traditional upfront-plus-milestones template. Clinical milestones remain the largest component of total deal value, and in our data, the gap between "biobucks" headlines and realistic achievable value remains substantial. For a typical preclinical or Phase I single-asset deal, the achievable portion of total announced deal value — accounting for clinical success probabilities and commercial milestone thresholds — is a fraction of the headline number.

There's also a meaningful difference in termination provisions. Platform deals tend to include technology reversion clauses that let the biotech recapture targets the buyer hasn't exercised options on. These clauses are powerful if well-drafted, because they ensure the platform holder retains value even if the partnership underperforms. Single-asset deals rarely include analogous provisions — the buyer either advances the program or shelves it, and the seller has limited recourse.

These benchmarks are available in real-time on Solidus, our deal terms platform.

Who's Buying — and What They're Optimizing For

The buyer landscape for platform deals looks different from single-asset acquisitions. Large-cap pharma (top 20 by market cap) dominates platform transactions, which makes sense — only companies with large enough pipelines can fully exploit a multi-target engine. Mid-cap pharma and large biotechs are more active in single-asset licensing, where they're solving a specific pipeline gap rather than building infrastructure.

What's shifted recently is that several large-cap buyers have moved from a "build the platform internally" approach to a "buy or partner for platform access" approach. Roche's decision to partner externally for certain degrader capabilities, despite having significant internal chemistry resources, signals that even well-resourced buyers see speed-to-access as more valuable than internal control. That's a meaningful shift, and it supports platform valuations.

The exception is gene editing, where the largest buyers — particularly Vertex after its CASGEVY launch — have opted to build internally rather than pay platform premiums to external holders. When a buyer already has a scaled, validated platform in-house, the premium for external platforms collapses. Founders in gene editing need to be clear-eyed about this dynamic: the addressable buyer universe for editing platforms is smaller than it looks.

Implications

If you're running a platform-based biotech and preparing for a licensing process or sale, three things matter.

First, modality selection is destiny for your deal economics. ADC, protein degradation, and differentiated cell therapy manufacturing platforms are commanding genuine premiums — higher upfronts, better option economics, and more favorable structural terms. Computational discovery platforms, by contrast, are being priced like services businesses unless there is differentiated clinical-stage data attached. If your platform doesn't fall into a premium category, the most important thing you can do is generate proprietary clinical proof-of-concept data on at least one internal program, because that converts an abstract platform story into a concrete asset story.

Second, structure your deal to capture the option value you're creating. If a buyer wants access to your engine across multiple targets, the option-exercise payments for each subsequent target should reflect the value of the work you've done to derisk the platform. Too many biotechs give away target optionality for modest incremental payments because they're focused on maximizing the headline number. A well-structured option deal with meaningful per-target payments and technology reversion rights will generate more total value than a big-headline deal with a long, improbable milestone stack.

Third, know your buyer universe and what each buyer is optimizing for. Large-cap pharma buyers will pay platform premiums because they can exploit the technology across a broad pipeline. Mid-cap buyers may not have enough targets to justify platform economics, which means they'll push you toward single-asset terms even if you're selling a platform. If your natural buyer set is mid-cap companies, consider whether a multi-party non-exclusive licensing strategy — selling platform access to several buyers simultaneously — generates more value than an exclusive partnership with one.

The window for platform premiums in the strongest modalities remains open, but it's worth noting that as more clinical data accumulates across ADC and degrader platforms, the market will increasingly differentiate between platforms with validated chemistry and those still running on preclinical promise. The time to transact is when your platform has demonstrated differentiation but before the category becomes commoditized. For several hot modalities, that window is narrowing.